Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.36 |
| ▸ | LPL | P06858 | 6/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22655171 | 0.80 | SELL (0.37) | HIF1ALIPGLPLTRPA1 | |
| SCHEMBL30412775 | 0.80 | SELL (0.37) | HIF1ALIPGLPLTRPA1 | |
| SCHEMBL31088896 | 0.77 | LPL (0.39) | HIF1ALIPGLPL | |
| SCHEMBL30916355 | 0.77 | HIF1A (0.32) | HIF1A | |
| SCHEMBL22654841 | 0.74 | IL1B (0.33) | HIF1ALIPGLPLF11 | |
| SCHEMBL31200594 | 0.74 | TRPA1 (0.41) | HIF1ATRPA1 | |
| SCHEMBL31200686 | 0.74 | CYP3A4 (0.44) | HIF1A | |
| SCHEMBL30054842 | 0.74 | IL1B (0.33) | HIF1ALIPGLPLF11 | |
| SCHEMBL31200655 | 0.74 | ALDH1A1 (0.39) | HIF1ALIPGLPL | |
| SCHEMBL5840583 | 0.73 | CYP3A4 (0.38) | HIF1ALIPGLPLF11ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680601-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | Sanofi (FR) | 2026-01-21 | — | — | EP | disclosed |
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-10-31 | — | — | US | disclosed |
| WO-2024188994-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | NLRP3, NOD1, NLRP1 | HIF1A 3960/4885LIPG 4608/4885LPL 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.